Cheshire firm in multimillion-pound US link for treatment of diabetes in dogs

Ian Page, chief executive, Dechra Pharmaceuticals

Northwich vet supplies firm Dechra Pharmaceuticals has signed a licensing and supply deal with US firm Akston Biosciences Corporation for a long-acting protein in the treatment of diabetes in dogs.

Following an initial upfront payment of $2m, there are subsequent milestone payments totalling $14m due on the achievement of major milestones in the development process, which should be completed within five years.

Furthermore, Dechra anticipates product development spend to increase by approximately £20m spread over the next four years in order to achieve marketing authorisations in the United States and European Union, and subsequently other global markets.

Diabetes is currently treated by daily injections. However, proof of concept studies conducted to date indicate that a single injection of this long-acting protein will have a duration of seven days, providing a clear advantage over current treatments to both the dog owner and the dog’s welfare.

Under the terms of the agreement Dechra also has the option to license a version for cats, which will be subject to additional milestones.

Dechra chief executive, Ian Page, said: “We are delighted to have secured this major development opportunity which will further enhance Dechra’s position as world leaders in veterinary endocrinology.

“Once approved this will become the most significant product in our portfolio as we continue to build our portfolio of novel drugs.”

Akston’s chief executive, Todd Zion, said: “We are pleased to have found a strong partner in Dechra to co-develop and commercialise our novel ultra-long acting insulin technology.

“Once approved, this will become a key asset in our platform of engineered insulin products.”

Akston were advised on the transaction by Oriole Advisors.

Click here to sign up to receive our new South West business news...
Close